Foundational guide
Buy Selank Nasal Spray: The Test List Changes With the Format
A spray and a lyophilised vial are not two packagings of one product. They are two objects with two different analytical burdens, and the format you choose decides which questions a certificate is even capable of answering.
Search to buy Selank nasal spray and you are shopping for a different object than the one most research suppliers list. A spray is an aqueous solution already made up and sealed into a metered pump. A vial is lyophilised solid. The distinction is not packaging preference; it decides which analyses a certificate is capable of carrying.
This page is about that difference and nothing else. There are no preparation instructions here, no quantities, and no account of what either format does in a person. What there is, is a comparison of the documentary burden each one carries and an honest statement of which one the supplier below actually sells.
The listing this page assesses, which is the vial rather than a spray:
Supplier publishing lot-level data
Selank, Ascension Peptides
Every lot carries certificates from two independent laboratories. The code below halves the listed price on the vial.
The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Kovera Labs and MZ Biolabs certificates per lot
- Carriage free above $250
- Dispatched same day before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified August 21, 2026.
What you are actually buying when you buy Selank nasal spray
Set the two formats side by side as objects rather than as products and the asymmetry is immediate. One is a characterised solid. The other is a formulation, a device and a shelf life bundled together.
| Property | Lyophilised vial | Metered nasal spray |
|---|---|---|
| Physical state as sold | Dry solid under a stopper, stable at depressed temperature | Aqueous solution at an unstated concentration, in contact with a pump assembly |
| What can be assayed on the item as sold | Identity, chromatographic purity, quantity per vial, and for parenteral intent bacterial endotoxin | The same chemistry in principle, plus everything the formulation adds, and in practice almost none of it is published |
| Excipients present | Whatever was added for solubility and buffering, which ultraviolet detection does not see and which the certificate for the current lot says outright are not counted as impurities | A preservative system, tonicity and buffering agents, sometimes a permeation aid, usually undeclared on a research listing |
| Clock that starts at manufacture | Slow. Degradation in the dry state is the constraint | Faster. Hydrolysis and microbial ingress both become live once the peptide is in water, which is why the fill date matters and is rarely stated |
| Traceability to a lot | A lot number on the vial that can be matched against a published certificate | Frequently a batch code with no corresponding document, and no way to tell which raw material went into it |
The last row is the one that decides the purchase for a reader who cares about evidence. A spray is one step further from the raw material than a vial is, and each step adds a party whose records you cannot see. Where a repackager sits between the synthesis and the label, the lot trail is where the break happens, which is the same failure we traced in the point at which a BPC-157 lot trail breaks.
The questions a solution raises that a powder does not
FDA's chemistry, manufacturing and controls guidance for nasal spray drug products runs to forty-nine pages, and its table of contents is the most compact statement available of what characterising a spray involves. It addresses container closure systems, preservative effectiveness and sterility maintenance, microbial limits, priming and repriming in different orientations, the effect of resting time between uses, temperature cycling, plume geometry, particle size distribution after storage, behaviour as the container nears exhaustion, photostability and device robustness.
None of that applies to a research-supply product, because the guidance governs approved drug applications and no such application exists for this compound. That is exactly why it is useful here. It enumerates the questions a metered spray raises by virtue of being a metered spray, and a consumer product sold without an application has answered none of them, whether or not the peptide inside it is real.
Three of those questions have no analogue at all in the vial case. What preservative keeps a multi-dose aqueous product from supporting growth between openings. Whether the delivered amount per actuation is consistent from the first press to the last. Whether the peptide survives in solution for the period the product is sold over, which for a compound whose published stabilisation strategy is a proline-rich tail added to slow enzymatic breakdown is not an idle question. The tail addresses enzymes, not hydrolysis in a bottle.
Route decides the test list, and the regulator says so explicitly
FDA's published assessment of selank acetate is careful about route in a way that most summaries of it are not. The agency wrote that compounded drugs containing the substance may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, and that it lacks important information regarding any safety issues raised by selank acetate administered to humans. The qualifier “for certain routes” is doing real work. Immunogenic risk from aggregates is a parenteral concern first.
Follow that logic and the test lists diverge cleanly. Anything intended for injection needs a bacterial endotoxin result, because endotoxin is pyrogenic by that route and is the subject of FDA's own questions and answers on pyrogen testing. A nasal product is not held to an endotoxin limit, but inherits microbial limits and preservative effectiveness instead, because a multi-dose bottle opened repeatedly is a different microbiological problem from a sealed single-use vial. Neither list is a superset of the other, and a seller who tells you a spray is safer because it is not injected has answered a question nobody asked.
The route-dependence is not only regulatory. It is the reason a rodent comparison of intranasal against intraperitoneal administration was worth publishing at all, and the general principles are set out in our guide to how subcutaneous, intramuscular and intranasal routes differ. What a route does to the fraction of a dose that reaches circulation is a separate matter again, covered in our explanation of peptide bioavailability. Neither page, and not this one, makes any claim about outcomes in people.
What the supplier above sells, and what its certificate covers
A vial, not a spray. Ten milligrams of lyophilised material, listed at $47.50 and $23.75 with the code, supplied under research-use terms. Saying so plainly is the least a page carrying an affiliate link owes a reader who arrived looking for a bottle with a pump on it.
The published certificate for lot 29-01260229, analysed on 7 February 2026, reports purity of 99.32 percent by chromatography with ultraviolet detection, identity confirmed by mass spectrometry at a measured monoisotopic mass of 751.47 Da against an expected 751.43, and a measured quantity of 12.29 mg in a vial labelled 10 mg. That is a genuine analysis from a named laboratory with a visible trace, and it is more than most of this market publishes.
It carries no bacterial endotoxin result and no sterility screen. The same supplier’s June batch 29-05260628, certified in a separate document, carries both: a kinetic chromogenic endotoxin assay performed to USP Chapter 85 reporting below 0.20 EU/mL against a limit of 0.5 across a 2.0 mL dilution volume, and a rapid two-day sterility screen recording no growth whose own report says full USP Chapter 71 testing may still be required. One compound, two batches, two standards of documentation, which is why the habit worth keeping is to read every certificate shown on a product page rather than only the one that is a clickable link. Our breakdown of what the vial costs per milligram sets that gap against the price, and what research-use supply actually means explains the terms both products are sold under. Nothing on this page describes or implies human use of either format.
Frequently asked questions
- Is Selank nasal spray the same product as a Selank vial?
- No. A vial holds lyophilised solid, which is a stable form that can be assayed for identity, chromatographic purity and quantity as it sits. A spray holds an aqueous solution already made up in a metered pump, which is a formulated product with a preservative question, a container closure question and a stability-in-solution question that a powder does not have. They are different objects, and a certificate written for one does not answer the questions raised by the other.
- Why is the nasal spray the common consumer format?
- Because it removes every step between purchase and use, and because the intranasal route has been the one studied in the Russian literature on this peptide, including a rodent comparison of intranasal against intraperitoneal administration. Convenience is the whole of the commercial logic. It also means the buyer inherits a formulation someone else made, with no visibility into when it was made up or what was added to keep it stable.
- Does a nasal spray need to be sterile?
- Nasal sprays are not held to the sterility and bacterial endotoxin requirements that govern injectables, but they are not unregulated either. FDA's chemistry and manufacturing guidance for approved nasal spray products addresses preservative effectiveness and sterility maintenance, microbial limits, container closure systems, and behaviour under priming, repriming and storage. The relevant test list is different from the injectable one rather than absent, and a research-supply spray sold without a certificate has met none of it.
- Does the supplier linked from this page sell a Selank spray?
- No, and we would rather say so than imply otherwise. What is sold is a 10 mg lyophilised vial, listed at $47.50 and $23.75 with the code, supplied for laboratory research use. If a spray is specifically what you are looking for, this listing is not it, and the honest thing a review page can do is tell you that before you reach a checkout.
- What should a certificate for either format actually show?
- For the lyophilised vial: identity by mass spectrometry against the expected monoisotopic mass, chromatographic purity with the trace visible, a measured quantity, a named laboratory, an analysis date and a lot number that matches the vial in your hand. For any product intended for a parenteral route, a bacterial endotoxin result as well. For a solution in a pump, add the questions that only a formulated liquid raises: what preservative system is present, how the product behaves over its shelf life, and when the batch was filled.
Limitations of the evidence
This page compares what two product formats can be documented to, not what either does in a person. It contains no preparation, handling or dosing instructions of any kind, and nothing in it describes or implies human use. We have not tested a nasal spray product, opened one, or examined the certificate of any spray on the market, so every statement about consumer sprays describes the class of product and the documentation it typically travels with rather than a named item. The rodent route comparison cited here is listed because such a comparison exists in the literature, not for any result, which we have not read in full. The vendor certificate observations describe the specific lot documents published at the review date. Selank holds no FDA approval for any indication, its nomination for the 503A bulks list was withdrawn, and the FDA nasal spray guidance cited applies to approved drug products and not to research-supply material.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.National Center for Biotechnology Information · PubChem Compound Summary for CID 11765600, Selank · PubChem · 2026Validated
- 2.U.S. Food and Drug Administration, Center for Drug Evaluation and Research · Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products: Chemistry, Manufacturing, and Controls Documentation · 2002Validated
- 3.U.S. Food and Drug Administration · Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks · 2026Validated
- 4.U.S. Food and Drug Administration · Pyrogen and Endotoxins Testing: Questions and Answers · 2012Validated
- 5.Vasil'eva EV, Kondrakhin EA, Salimov RM, Kovalev GI · Comparison of pharmacological effects of heptapeptide Selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice · Eksperimental'naia i Klinicheskaia Farmakologiia · 2016PMID 29787664Preclinical
- 6.Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N · Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity · Protein and Peptide Letters · 2018PMID 30255741DOI 10.2174/0929866525666180925144642Preclinical